Страна: Канада
Език: английски
Източник: Health Canada
VERAPAMIL HYDROCHLORIDE
MYLAN PHARMACEUTICALS ULC
C08DA01
VERAPAMIL
120MG
TABLET (EXTENDED-RELEASE)
VERAPAMIL HYDROCHLORIDE 120MG
ORAL
100
Prescription
MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS
Active ingredient group (AIG) number: 0113846001; AHFS:
APPROVED
2009-07-03
_Mylan-Verapamil_ _ _ _SR (verapamil hydrochloride) Product Monograph_ _ _ _Page 1 of 42 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR MYLAN-VERAPAMIL SR Verapamil hydrochloride sustained-release tablets Sustained-release tablets, 120 mg, 180 mg and 240 mg, oral Mylan Standard _ _ Antihypertensive Agent Mylan Pharmaceuticals ULC 85 Advance Road Etobicoke, Ontario M8Z 2S6 Submission Control Number: 263850 Date of Initial Authorization: February 12, 1996 Date of Revision: June 10, 2022 _ _ _Mylan-Verapamil _ _ _ _SR (verapamil hydrochloride) Product Monograph_ _ _ _Page 2 of 42_ RECENT MAJOR LABEL CHANGES CONTRAINDICATIONS WARNINGS AND PRECAUTIONS TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics ................................................................................................................... 4 1.2 Geriatrics ................................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION ................................................................................. 5 4.1 Dosing Considerations .............................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment ......................................................... 6 4.4 Administration ............................... Прочетете целия документ